Therapeutic strategy to ‘counter the counterattack’: Further upregulate Fas expression in tumors with epigenetic therapies. In addition to epigenetic inhibition, other strategies include viral mediated delivery of Fas or fusion proteins connecting FasL to a single chain antibody fragment that specifically recognizes tumor cells or tumor stroma antigens is a promising field of research in therapeutics. Upon binding, the initially inactive protein would convert into a protein with membrane-bound-FasL-like activity.